CL2019002318A1 - Administración subcutánea de un antagonista del receptor p2y12. - Google Patents

Administración subcutánea de un antagonista del receptor p2y12.

Info

Publication number
CL2019002318A1
CL2019002318A1 CL2019002318A CL2019002318A CL2019002318A1 CL 2019002318 A1 CL2019002318 A1 CL 2019002318A1 CL 2019002318 A CL2019002318 A CL 2019002318A CL 2019002318 A CL2019002318 A CL 2019002318A CL 2019002318 A1 CL2019002318 A1 CL 2019002318A1
Authority
CL
Chile
Prior art keywords
pyrimidin
phenyl
receptor antagonist
subcutaneous administration
cyclopropil
Prior art date
Application number
CL2019002318A
Other languages
English (en)
Spanish (es)
Inventor
Martine Baumann
Markus Kramberg
Markus Rey
Markus Riederer
Sebastien Roux
Original Assignee
Idorsia Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Idorsia Pharmaceuticals Ltd filed Critical Idorsia Pharmaceuticals Ltd
Publication of CL2019002318A1 publication Critical patent/CL2019002318A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays or needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CL2019002318A 2017-03-15 2019-08-16 Administración subcutánea de un antagonista del receptor p2y12. CL2019002318A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP2017056175 2017-03-15

Publications (1)

Publication Number Publication Date
CL2019002318A1 true CL2019002318A1 (es) 2020-01-10

Family

ID=61899166

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2019002318A CL2019002318A1 (es) 2017-03-15 2019-08-16 Administración subcutánea de un antagonista del receptor p2y12.

Country Status (18)

Country Link
US (1) US11179390B2 (enExample)
EP (1) EP3595666A1 (enExample)
JP (2) JP7580918B2 (enExample)
KR (1) KR102510832B1 (enExample)
CN (1) CN110381947A (enExample)
AU (1) AU2018234056B2 (enExample)
BR (1) BR112019014567A2 (enExample)
CL (1) CL2019002318A1 (enExample)
EA (1) EA201992123A1 (enExample)
IL (1) IL269286B2 (enExample)
MA (1) MA49887A (enExample)
MX (1) MX393334B (enExample)
MY (1) MY205605A (enExample)
PH (1) PH12019502111A1 (enExample)
SG (1) SG11201908128YA (enExample)
TW (1) TWI765002B (enExample)
UA (1) UA125531C2 (enExample)
WO (1) WO2018167139A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109715639B (zh) 2016-09-22 2022-04-19 爱杜西亚药品有限公司 结晶形式
TWI905227B (zh) * 2020-07-15 2025-11-21 新加坡商暉致亞太私人有限公司 包含p2y12受體拮抗劑的水性醫藥組合物
CA3223733A1 (en) 2021-07-13 2023-01-19 Nicole Blumer A process for the synthesis of 4-((r)-2-{[6-((s)-3-methoxy-pyrrolidin-1-yl)-2-phenyl- pyrimidine-4-carbonyl]-amino}-3-phosphono-propionyl)-piperazine-1 -carboxylic acid butyl ester
CN118871446A (zh) 2022-03-14 2024-10-29 晖致亚太私人有限公司 (r)-2-((叔丁氧基羰基)氨基)-3-(二乙氧基磷酰基)丙酸或其膦酸酯衍生物的合成方法

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3870035A (en) 1970-07-17 1975-03-11 Survival Technology Method and apparatus for self-administering pre-hospital phase treatment of coronary prone individuals in the early minutes or hours after the onset of heart attack symptoms
US4004577A (en) 1972-12-04 1977-01-25 Survival Technology, Inc. Method of treating heart attack patients prior to the establishment of qualified direct contact personal care
JPS5373586A (en) 1976-12-09 1978-06-30 Mitsubishi Chem Ind Ltd New penicillin derivatives
US5078680A (en) 1984-08-08 1992-01-07 Survival Technology, Inc. Automatic injector for emergency treatment
US4795433A (en) 1985-05-20 1989-01-03 Survival Technology, Inc. Automatic injector for emergency treatment
US4658830A (en) 1984-08-08 1987-04-21 Survival Technology, Inc. Method and apparatus for initiating reperfusion treatment by an unattended individual undergoing heart attack symptoms
GR861289B (en) 1985-05-20 1986-09-16 Survival Technology Injection method and apparatus with electrical blood absorbing stimulation
CA2020437A1 (en) 1989-07-05 1991-01-06 Yoshihide Fuse Cinnamamide derivative
CA2375920A1 (en) 1999-06-14 2000-12-21 Eli Lilly And Company Compounds
US6861424B2 (en) 2001-06-06 2005-03-01 Schering Aktiengesellschaft Platelet adenosine diphosphate receptor antagonists
CN1747732A (zh) 2002-12-11 2006-03-15 舍林股份公司 作为血小板腺苷二磷酸受体拮抗剂的2－氨基羰基喹啉化合物
WO2004092189A1 (en) 2003-04-09 2004-10-28 Wyeth Derivatives of 2-(8,9-dioxo-2,6-diazabicyclo(5.2.0)non-1(7)-en-2-yl)alkyl phosphonic acid and their use as n-methyl-d-aspartate (nmda) recetor antagonists
WO2005002574A1 (en) 2003-06-24 2005-01-13 Actelion Pharmaceuticals Ltd Pyrazolidinedione derivatives and their use as platelet aggregation inhibitors
TW200640877A (en) 2005-04-28 2006-12-01 Actelion Pharmaceuticals Ltd Pyrimidine derivatives
ES2421448T3 (es) 2005-10-21 2013-09-02 Actelion Pharmaceuticals Ltd Derivados de piperazina como agentes contra la malaria
CL2007002920A1 (es) 2006-10-13 2008-06-06 Actelion Pharmaceuticals Ltd Compuestos derivados de 2-aminocarbonilpiridina; composicion farmaceutica; y uso para el tratamiento de trastornos vasculares oclusivos.
AR063518A1 (es) 2006-10-25 2009-01-28 Actelion Pharmaceuticals Ltd Derivados 2-fenil-6-aminocarbonil-pirimidina; composicion farmaceutica; y su uso para tratar y/o prevenir enfermedades vasculares perifericas viscerales, hepaticas y renales, enfermedades cardiovasculares y enfermedades cerebrovasculares asociados con la agregacion de plaquetas, incluyendo trombosis
JP4785881B2 (ja) 2007-02-27 2011-10-05 大塚製薬株式会社 医薬
CA2684644A1 (en) 2007-04-23 2008-10-30 Sanofi-Aventis Quinoline-carboxamide derivatives as p2y12 antagonists
US20090048216A1 (en) 2007-05-02 2009-02-19 Portola Pharmaceuticals, Inc. Intravenous and oral dosing of a direct-acting and reversible p2y12 inhibitor
RU2483072C2 (ru) 2007-11-29 2013-05-27 Актелион Фармасьютиклз Лтд Производные фосфоновой кислоты и их применение в качестве антагонистов рецептора p2y12
EP2238127B1 (en) 2007-12-26 2012-08-15 Sanofi Pyrazole-carboxamide derivatives as p2y12 antagonists
EP2238128B1 (en) 2007-12-26 2012-08-22 Sanofi Heterocyclic pyrazole-carboxamides as p2y12 antagonists
AR071652A1 (es) 2008-04-11 2010-07-07 Actelion Pharmaceuticals Ltd Derivados 2- fenil-piridina substituidos
AR071653A1 (es) 2008-04-11 2010-07-07 Actelion Pharmaceuticals Ltd Derivados 2-fenil-4-ciclopropil-pirimidina
MX2011010200A (es) 2009-04-08 2011-10-14 Actelion Pharmaceuticals Ltd 6-(3-aza-biciclo[3.1.0]hex-3-il)-2fenil-pirimidinas como antagonistas del receptor de adenosina 5'-difosfato (adp).
JP5536876B2 (ja) 2009-04-22 2014-07-02 アクテリオン ファーマシューティカルズ リミテッド チアゾール誘導体及びｐ２ｙ１２受容体拮抗剤としてのそれらの使用
WO2011137459A1 (en) * 2010-04-30 2011-11-03 Portola Pharmaceuticals, Inc. Dosage forms of elinogrel and methods of injectable administration thereof
EP2585161A1 (en) 2010-06-23 2013-05-01 Stefan Kralev Medical device for self-administration of patients with acute coronary events
CN109715639B (zh) 2016-09-22 2022-04-19 爱杜西亚药品有限公司 结晶形式

Also Published As

Publication number Publication date
JP2020510043A (ja) 2020-04-02
US20200129510A1 (en) 2020-04-30
JP2023052576A (ja) 2023-04-11
IL269286B2 (en) 2023-08-01
MA49887A (fr) 2020-06-24
IL269286A (en) 2019-11-28
MX2019009559A (es) 2019-10-15
KR20190124297A (ko) 2019-11-04
WO2018167139A1 (en) 2018-09-20
JP2025060907A (ja) 2025-04-10
MX393334B (es) 2025-03-24
MY205605A (en) 2024-10-29
IL269286B1 (en) 2023-04-01
SG11201908128YA (en) 2019-10-30
UA125531C2 (uk) 2022-04-13
AU2018234056A1 (en) 2019-10-31
TW201840323A (zh) 2018-11-16
NZ757938A (en) 2024-07-05
EP3595666A1 (en) 2020-01-22
BR112019014567A2 (pt) 2020-02-18
JP7580918B2 (ja) 2024-11-12
AU2018234056B2 (en) 2023-05-25
TWI765002B (zh) 2022-05-21
PH12019502111A1 (en) 2020-03-16
CA3050831A1 (en) 2018-09-20
CN110381947A (zh) 2019-10-25
JP7902762B2 (ja) 2026-08-10
KR102510832B1 (ko) 2023-03-15
EA201992123A1 (ru) 2020-02-25
US11179390B2 (en) 2021-11-23

Similar Documents

Publication Publication Date Title
CL2021000566A1 (es) Procesos para fabricar ácido 2-((3r,5r,6s)-5-(3-clorofenil)-6-(4-clorofenil)-1-((s)-1-(isopropilsulfonil)-3-metilbutan-2-il)-3-metil-2-oxopiperidin-3-il)acético, intermediarios y procesos para fabricar los intermediarios, formas cristalinas del compuesto y los intermediarios. (divisional de la solicitud no. 2015003589)
MX2021003241A (es) Sal de tosilato de pirrolo[2,3-d]pirimidina, forma cristalina de la misma y proceso de fabricacion e intermediario al mismo.
UY36176A (es) Formas cristalinas de (2r, 5s, 13ar)-8-hidroxi-7,9- dioxo- n-(2,4,6 - trifluorobencil)-2,3,4,5,7,9,13,13a -octahidro -2,5- metanopirido[1?,2?,4,5]pirazino[2,1-b][1,3]oxazapina- 10-carboxamida
CR20210381A (es) MOLÉCULA DE UNIÓN AL ANTÍGENO MULTIESPECÍFICA QUE TIENE ACTIVIDAD DE SUSTITUCIÓN DE LA FUNCIÓN DE COFACTOR DEL FACTOR VIII DE COAGULACIÓN DE SANGRE (FVIII) Y FORMULACIÓN FARMACÉUTICA QUE CONTIENE TAL MOLÉCULA COMO INGREDIENTE (Divisional Exp. 2020-0158)
CL2009001212A1 (es) Compuestos derivados de pirrolo[2,3-d]pirimidina, inhibidores de cinasas; composicion farmaceutica que los comprende; y su uso en el tratamiento de demencia vascular, trastorno del snc, cancer, entre otras.
UY37927A (es) Proceso para la preparación de 6-(2-hidroxi-2-metilpropoxi)-4-(6-(6-((6-metoxipiridin-3-il)metil)-3,6-diazabiciclo[3.1.1]heptan-3-il)piridin-3-il)pirazolo[1,5-a]piridina-3-carbonitrilo
GT201400301A (es) 7h-pirrolo [2,3-d] pirimidinas-4- ( aminho-substituidas) novedosas como inhibidores de lrrk2
MX2022014277A (es) Metodos para una mejor administracion de agentes activos a tumores.
MX373318B (es) 5-bromo-2,6-di-(1h-pirazol-1-il) pirimidin-4-amina-para su uso en el tratamiento del cáncer.
NZ630205A (en) Enhancer of zeste homolog 2 inhibitors
MY184292A (en) Substituted aminopyrimidine compounds and methods of use
TN2015000355A1 (fr) Derives de pyrrolo [2, 3-d] pyrimidine servant d'inhibiteurs de kinases de type janus (jak)
MX373865B (es) Compuesto novedoso de pirazolo[3,4-d] pirimidina o sal del mismo
BR112017013382A2 (pt) método para preparar um composto, composto, e, ácido.
MX2016009529A (es) Hibridosomas, composiciones que comprenden los mismos, procesos para su produccion y usos de los mismos.
CO2018005163A2 (es) Compuesto de [1,2,4]triazolo[1,5-a]pirimidin-7-ilo
MX385576B (es) Derivados de [1,2,4]triazol[1,5-a]pirimidina como inhibidores de pde2
ECSP14013263A (es) Inhibidores de la enzima activadora de nedd8
CL2018003421A1 (es) Combinaciones farmacéuticas.
PH12019502111A1 (en) Subcutaneous administration of a p2y12 receptor antagonist
CY1126388T1 (el) Χρηση delgocitinib για την θεραπεια χρονιουεκζεματος χεριων
ECSP21014902A (es) Moduladores del receptor nmda heteroaromático y usos de los mismos
CO2018007112A2 (es) Composiciones farmacéuticas que comprenden derivados de fenilaminopirimidina
MX2019007452A (es) Proceso para preparar derivados de 7h-pirrolo[2,3-d]pirimidina y co-cristales de los mismos.
CL2018000856A1 (es) Derivados de éter cíclico de pirazolo[1,5-a]pirimidin-3-carboxiamida.